Peripheral T-cell lymphoma · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Gemcitabine monotherapy Variant #20 | — | R 14 213 | 56d | — | — | — | — | 1 |
Bendamustine monotherapy Variant #01 | — | R 5 419 | — | ~16.5 mo | — | — | — | 2 |
DHAP Variant #01 | — | R 3 777 | 28d | — | — | — | — | — |
GDP Variant #01 | — | R 3 565 | 21d | — | — | — | — | — |
Pralatrexate monotherapy N/A - secondary systemic drug | — | R 0 | 49d | — | — | — | — | 1 |
Romidepsin monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | 1 |
6 of 6 regimens shown